Ridinilazole Explained

Iupac Name:2,2'-Di(pyridin-4-yl)-1H,1H-5,5'-bi(benzimidazole)
Width:275
Cas Number:308362-25-6
Chemspiderid:17592423
Atc Prefix:None
Pubchem:16659285
Kegg:D11958
Synonyms:SMT19969
Unii:06DX01190R
C:24
H:16
N:6
Smiles:c6cc(c5nc4ccc(c3ccc2nc(c1ccncc1)[nH]c2c3)cc4[nH]5)ccn6

Ridinilazole (previously known as SMT19969) is an investigational small molecule antibiotic being evaluated for oral administration to treat Clostridioides difficile infection (CDI). In vitro, it is bactericidal against C. difficile and suppresses bacterial toxin production; the mechanism of action is thought to involve inhibition of cell division.[1] It has properties which are desirable for the treatment of CDI, namely that it is a narrow-spectrum antibiotic which exhibits activity against C. difficile while having little impact on other normal intestinal flora and that it is only minimally absorbed systemically after oral administration. At the time ridinilazole was developed, there were only three antibiotics in use for treating CDI: vancomycin, fidaxomicin, and metronidazole. The recurrence rate of CDI is high, which has spurred research into other treatment options with the aim to reduce the rate of recurrence.[2] [3]

, two phase II trials have been completed and two phase III trials comparing ridinilazole to vancomycin for CDI are expected to be completed in September 2021.[4] [5] Ridinilazole was designated as a Qualified Infectious Disease Product (QIDP) and was granted Fast Track status by the U.S. FDA. Fast Track status is reserved for drugs designed to treat diseases where there is currently a gap in the treatment, or a complete lack thereof.[6] The QIDP designation adds five more years of exclusivity for ridinazole upon approval.[7]

See also

Notes and References

  1. Cho JC, Crotty MP, Pardo J . Clostridium difficile infection . Annals of Gastroenterology . 32 . 2 . 134–140 . March 2019 . 30837785 . 6394264 . 10.20524/aog.2018.0336 .
  2. Bassères E, Endres BT, Dotson KM, Alam MJ, Garey KW . Novel antibiotics in development to treat Clostridium difficile infection . Current Opinion in Gastroenterology . 33 . 1 . 1–7 . January 2017 . 28134686 . 10.1097/MOG.0000000000000332 . 32454489 . These tables highlight the increased drug development directed towards CDI due to the rise in prevalence of infections and to attempt to reduce the number of recurrent infections. .
  3. Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH . Ridinilazole: a novel therapy for Clostridium difficile infection . International Journal of Antimicrobial Agents . 48 . 2 . 137–43 . August 2016 . 27283730 . 10.1016/j.ijantimicag.2016.04.026 . there exists a significant unmet and increasing medical need for new therapies to treat CDI, specifically those that can reduce the rate of disease recurrence. . free .
  4. Carlson TJ, Endres BT, Bassères E, Gonzales-Luna AJ, Garey KW . Ridinilazole for the treatment of Clostridioides difficile infection . Expert Opinion on Investigational Drugs . 28 . 4 . 303–310 . April 2019 . 30767587 . 10.1080/13543784.2019.1582640 . 73422150 .
  5. Collins DA, Riley TV . Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile . Letters in Applied Microbiology . 75 . 3 . 526–536 . September 2022 . 35119124 . 9541751 . 10.1111/lam.13664 .
  6. Web site: 2018-11-03 . Fast Track . U.S. Food and Drug Administration .
  7. Web site: HHS spurs new antibiotic development for biodefense and common infections . 2020-12-04. Public Health Emergency . U.S. Department of Health and Human Services .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ridinilazole".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.